HomeCompareMNTV vs ABBV

MNTV vs ABBV: Dividend Comparison 2026

MNTV yields 21.16% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $23.9K in total portfolio value· pulled ahead in Year 9
10 years
MNTV
MNTV
● Live price
21.16%
Share price
$9.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.4K
Annual income
$7,616.03
Full MNTV calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MNTV vs ABBV

📍 ABBV pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNTVABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNTV + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNTV pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNTV
Annual income on $10K today (after 15% tax)
$1,798.94/yr
After 10yr DRIP, annual income (after tax)
$6,473.63/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $14,582.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNTV + ABBV for your $10,000?

MNTV: 50%ABBV: 50%
100% ABBV50/50100% MNTV
Portfolio after 10yr
$90.4K
Annual income
$16,193.90/yr
Blended yield
17.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MNTV
Analyst Ratings
1
Buy
5
Hold
Consensus: Hold
Price Target
$7.41
-21.6% upside vs current
Range: $7.41 — $7.41
Altman Z
0.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNTV buys
0
ABBV buys
0
No recent congressional trades found for MNTV or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNTVABBV
Forward yield21.16%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$78.4K$102.3K
Annual income after 10y$7,616.03$24,771.77
Total dividends collected$45.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$7.41$256.15

Year-by-year: MNTV vs ABBV ($10,000, DRIP)

YearMNTV PortfolioMNTV Income/yrABBV PortfolioABBV Income/yrGap
1$12,816$2,116.40$11,550$430.00+$1.3KMNTV
2$16,249$2,535.02$13,472$627.96+$2.8KMNTV
3$20,390$3,003.62$15,906$926.08+$4.5KMNTV
4$25,339$3,522.54$19,071$1,382.55+$6.3KMNTV
5$31,204$4,091.28$23,302$2,095.81+$7.9KMNTV
6$38,097$4,708.64$29,150$3,237.93+$8.9KMNTV
7$46,137$5,372.68$37,536$5,121.41+$8.6KMNTV
8$55,447$6,080.79$50,079$8,338.38+$5.4KMNTV
9← crossover$66,158$6,829.80$69,753$14,065.80$3.6KABBV
10$78,405$7,616.03$102,337$24,771.77$23.9KABBV

MNTV vs ABBV: Complete Analysis 2026

MNTVStock

Momentive Global Inc. provides Software-as-a-Service solutions that help businesses turn stakeholder feedback into action in the United States and internationally. It offers survey software products under the SurveyMonkey brand, that enable customers to listen and take action on stakeholder feedback; GetFeedback CX platform, which enables companies to leverage in-the-moment customer feedback to engage and retain their customers; GetFeedback Essentials provides companies the tools to launch customer experience programs quickly by gathering feedback via email and across their websites, analyzing it in one place, and integrating with their Salesforce CRM platform; GetFeedback Pro, includes the Essentials features and adds feedback collection channels, advanced analytics, automation, and additional pre-built integrations; and GetFeedback Ultimate, comprises the GetFeedback Pro features and adds mobile apps as a feedback collection channel and enables single sign-on. The company also provides Audience panel, which enables organizations to collect and analyze real-time actionable data from targeted panelists; Purpose-built insights solutions offers a suite of solutions, such as brand and industry tracking, usage & attitudes, and concept, packaging, Ad, name, message, and logo design testing; TechValidate, a marketing content automation solution; SurveyMonkey Apply, an application management solution; and Wufoo that helps users create web and mobile forms, collect file uploads, and receive online payments. It serves financial services, internet, technology, healthcare, media and entertainment, consumer goods and retail, transportation and logistics, government agencies, manufacturing, energy, education, professional services, and non-profit organizations. The company was formerly known as SVMK Inc. and changed its name to Momentive Global Inc. in June 2021. Momentive Global Inc. was founded in 1999 and is headquartered in San Mateo, California.

Full MNTV Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MNTV vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNTV vs SCHDMNTV vs JEPIMNTV vs OMNTV vs KOMNTV vs MAINMNTV vs JNJMNTV vs MRKMNTV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.